Barclays analyst Matt Miksic raised the firm’s price target on Abbott (ABT) to $159 from $158 and keeps an Overweight rating on the shares following the Q1 report.. The company’s distributed manufacturing model and product line redundancies make its tariff risks more manageable, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories Reports Strong Q1 2025 Results
- Abbott Laboratories: Strong Buy Rating Amid Robust Financial Performance and Growth Potential
- Abbott price target raised to $137 from $135 at Jefferies
- Nvidia, AMD see charges due to new China export rules: Morning Buzz
- Abbott Laboratories: Strong Organic Growth and Strategic Positioning Drive ‘Buy’ Rating